Sildenafil citrate is under clinical development by Avenir Wellness Solutions and currently in Phase I for Erectile Dysfunction. According to GlobalData, Phase I drugs for Erectile Dysfunction have a 91% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Sildenafil citrate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Sildenafil citrate overview

Sildenafil is a benzenesulfonamide derivative acts as vasoactive agent. It is formulated as for oral dissolving film. Sildenafil is indicated for the treatment of erectile dysfunction.

Sildenafil is under development for the treatment of erectile dysfunction. The drug candidate is formulated as thin oral dissolving film. It acts by targeting phosphodiesterase type 5. It is developed based on CUREfilm ODF technology platform.

Avenir Wellness Solutions overview

Avenir Wellness Solutions (Avenir Wellness) is a pharmaceutical cannabis company that provides innovative drug delivery. Its technology enables drugs to bypass the gastrointestinal tract, avoiding gastrointestinal side effects and inactivation in the gut and liver. The company is headquartered in Sherman Oaks, California, the US.

For a complete picture of Sildenafil citrate’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.